Canada’s natural health products sector has spent two decades operating under a regulatory model built for a smaller, simpler industry. That model is now being rebuilt in plain sight. Through 2025 and into 2026, Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) has advanced a modernization agenda that reaches into nearly every commercial decision a retailer, brand or supplier makes — from what counts as a licensed product, to who carries the compliance burden, to where money will eventually flow under cost recovery. Two pieces of that agenda deserve immediate attention from anyone moving inventory: the updated Natural Health Product Raw Material Policy, and the broader risk-based framework now taking shape around it.

The headline for industry is deceptively simple. The regulator is moving the line that separates a raw ingredient from a finished, licensable product — and in doing so, it is moving the point at which licensing obligations, costs and liability attach. For a sector where margin is made or lost on sourcing decisions, that line is worth millions.

The raw material question that has dogged the industry

For years, suppliers and manufacturers have wrestled with a deceptively basic question: at what point does a botanical extract, a bulk powder or an imported compound stop being a raw material and become a natural health product that requires a product licence (and a Natural Product Number) and a site licence? The answer determines whether a company needs to file, pay, hold inventory differently, and accept the regulatory exposure that comes with a licensed product.

The updated Raw Material Policy answers that question by anchoring classification to intended purpose of use. Material that is imported or sold for further processing by manufacturers — not manufactured, sold or represented for use as a finished NHP — is treated as a raw material and does not trigger product and site licensing requirements. Companies that grow, harvest, clean, sort or import raw material, but do not produce something ready for consumer use, sit outside site licensing. The distinction is functional, not cosmetic: it is built around how a substance is represented and where it sits in the production chain.

What changed in 2025 is the clarity, not the principle. The NNHPD gathered input from practitioners and provincial licensing bodies to sharpen the line between raw materials and finished products, closing longstanding grey areas that had left importers and contract manufacturers guessing. For ingredient suppliers, that clarity is commercially meaningful — it reduces the risk of an unplanned licensing obligation appearing mid-supply-chain, and it lets distributors structure their catalogue and their representations with more confidence.

Modernization: from a one-time licence to lifecycle accountability

The Raw Material Policy does not stand alone. It is one component of a much larger shift in how Health Canada intends to regulate the category. The modernization framework signals a move toward oversight that is more flexible, more targeted, and more closely aligned with international regulatory norms. Crucially, the regulator is increasingly interested in how a company’s systems perform in practice — across formulation, licensing, manufacturing, distribution and post-market monitoring — rather than treating a granted licence as the finish line.

That reframing carries a clear commercial message. Licensing is no longer the endpoint of compliance. Companies are expected to maintain supply chain oversight — supplier qualification, quality agreements, traceability records, and documented processes for handling deviations and complaints — and to keep monitoring product performance, managing adverse reactions and updating risk assessments as new information emerges. The cost of compliance, in other words, is being spread across the life of the product rather than concentrated at the application stage. Brands that have historically treated regulatory work as a launch-phase expense will need to budget for it as an ongoing operating cost.

The GMP clock is already ticking

The most concrete near-term deadline sits in good manufacturing practices. On September 4, 2025, Health Canada published Version 4.0 of the Good Manufacturing Practices Guide for Natural Health Products (GUI-0158). The transition period runs through March 4, 2026, after which Version 3 is withdrawn and Version 4 becomes the sole reference document. Manufacturers, packagers and importers who have not already begun reviewing their procedures against the new guidance are now operating on borrowed time. For retailers, the second-order effect matters: suppliers who fall behind on GMP readiness become supply risks, and category managers should be asking their vendors where they stand.

Cost recovery: paused, not cancelled

Hanging over the entire modernization effort is the question of who pays. Health Canada’s proposed cost-recovery framework — which would have introduced pre-market evaluation fees, site licence fees, and an annual “right-to-sell” fee tied to each NPN — has been paused while the broader program adjustments continue. Implementation will not begin on the previously floated December 1, 2025 date, and no new start date has been confirmed. The reprieve is real, but it is temporary. The fee structure is explicitly tied to the program’s costing model, and it will be revisited once modernization settles. Smaller brands carrying long catalogues of low-velocity SKUs should be modelling now what an annual per-NPN fee would do to the economics of their tail products — because rationalizing a catalogue is far easier before a fee lands than after.

What this means for the business

For ingredient suppliers and distributors, the Raw Material Policy is an opportunity to compete on clarity. Vendors who can clearly document the intended-purpose status of what they sell, and who can show traceability and quality systems behind it, become lower-risk partners — and lower risk is increasingly a purchasing criterion, not just a compliance checkbox.

For brands and manufacturers, the lesson is to stop treating regulation as a gate and start treating it as a continuous operating discipline. The companies that build supply chain oversight, post-market vigilance and GMP readiness into their cost base now will absorb the modernization transition without disruption. Those that defer will face the GMP deadline, the eventual return of cost recovery, and heightened lifecycle scrutiny all at once.

For retailers and category managers, the framework is a quiet stocking signal. As compliance costs migrate across the product lifecycle and a per-NPN fee looms, expect supplier consolidation, pressure on marginal SKUs, and a flight to brands with mature regulatory operations. The shelves of 2027 will likely be stocked by the companies that read the 2026 framework correctly — fewer, better-capitalized suppliers with cleaner compliance stories. Smart buyers should be vetting vendor regulatory readiness today, not when a product gets pulled.

Health Canada’s message, read commercially, is consistent across every piece of the framework: the era of one-and-done compliance is closing. The winners will be the operators who treat regulatory rigour as a competitive asset rather than a cost centre — and who move while the rules are still being written.

Frequently Asked Questions

What is the NHP Modernization Framework?

It is Health Canada’s 2025–2026 initiative to modernize the regulation of natural health products. It replaces a model centred on one-time licensing with risk-based oversight that follows a product across its entire lifecycle — formulation, licensing, manufacturing, distribution and post-market monitoring — and aligns Canadian rules more closely with international regulatory norms.

What is Health Canada’s NHP Raw Material Policy?

The Raw Material Policy clarifies when a substance is treated as a raw material versus a finished natural health product. Classification turns on intended purpose of use: material imported or sold for further processing by manufacturers — not represented for use as a finished NHP — is a raw material and does not trigger product or site licensing requirements.

Does a raw material need an NPN or a site licence?

No. Under the policy, materials not manufactured, sold or represented for use as a finished NHP do not require a product licence (NPN) or a site licence. Activities such as growing, harvesting, cleaning, sorting or importing raw material — without producing something ready for consumer use — fall outside site licensing requirements.

When do the new GMP rules (GUI-0158 Version 4.0) take effect?

Health Canada published Version 4.0 of the Good Manufacturing Practices Guide for Natural Health Products on September 4, 2025. After a transition period, Version 3 is withdrawn and Version 4.0 becomes the sole reference document on March 4, 2026.

Are NHP cost recovery fees still happening?

They are paused, not cancelled. The proposed framework — pre-market evaluation fees, site licence fees, and an annual per-NPN “right-to-sell” fee — will not begin on the previously floated December 1, 2025 date, and no new start date has been confirmed. Because the fees are tied to the program’s costing model, they are expected to be revisited once modernization settles.

What should brands and retailers do now?

Treat compliance as an ongoing operating discipline rather than a launch-phase task: build supplier qualification, traceability, post-market vigilance and GMP readiness into the cost base before the March 2026 GMP deadline and the eventual return of cost recovery. Retailers should vet vendor regulatory readiness proactively and model the margin impact of a future per-NPN fee on low-velocity SKUs.